肝细胞癌中miR-574-5p的表达与作用及其与预后的关系
作者:
通讯作者:
作者单位:

华中科技大学同济医学院附属武汉中心医院 急诊创伤外科,湖北 武汉 430000

作者简介:

李乾,华中科技大学同济医学院附属武汉中心医院主治医师,主要从事消化系统疾病方面的研究。

基金项目:


Expression and action of miR-574-5p in hepatocellular carcinoma and its association with prognosis
Author:
Affiliation:

Department of Emergency and Trauma Surgery, the Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 音频文件
  • |
  • 视频文件
    摘要:

    背景与目的 研究表明,miR-574-5p与多种肿瘤预后密切相关,但尚未见miR-574-5p与肝细胞癌(HCC)的关系报道。因此,本研究初步探讨miR-574-5p在HCC中表达及其与患者预后的关系。方法 用qRT-PCR检测130例HCC与癌旁组织及HCC细胞系(HepG2、MHCC-97H)与正常肝细胞系(L-02)中miR-574-5p的表达,用X-tile软件在患者生存数据中确定miR-574-5p表达量的最佳截断值后,分析miR-574-5p表达水平与患者临床病理因素于术后生存率的关系。分析HCC患者预后的影响因素。用TargetScan预测miR-574-5p的靶基因,并用双荧光素酶报告基因实验验证与Western blot实验确证。结果 miR-574-5p表达水平在HCC癌组织中明显高于癌旁组织,在HCC细胞系中明显高于正常肝细胞系(均P<0.05)。miR-574-5p表达与TNM分期(P=0.002)和分化程度(P=0.000)明显有关。miR-574-5p高表达组的总生存率与无瘤生存率均明显低于miR-574-5p低表达组(均P<0.01)。单因素与多因素分析结果显示,miR-574-5p高表达(HR=4.101,95% CI=1.348~8.968,P=0.03)、III~IV期(HR=5.403,95% CI=1.266~13.860,P=0.02)及中低分化(HR=3.655,95% CI=2.165~6.984,P=0.00)是HCC患者总生存率的独立危险因素,miR-574-5p高表达(HR=7.168,95% CI=1.144~18.260,P=0.01)与III~IV期(HR=7.436,95% CI=1.123~20.916,P=0.00)是HCC患者无瘤生存率的独立危险因素。TargetScan软件发现FOG2存在和miR-574-5p直接结合位点,双萤光素酶报告基因实验表明FOG2是miR-574-5p的直接靶基因。Western blot结果显示,FOG2蛋白在HCC组织中的表达量低于癌旁组织;Pearson相关分析表明,HCC组织中miR-574-5p表达水平与FOG2蛋白表达水平呈负相关(r=-0.499,P<0.05)。结论 miR-574-5p在HCC中普遍升高,miR-574-5p高表达可作为HCC患者预后不良的分子标志物,miR-574-5p可能通过下调其靶基因FOG2发挥促癌作用。

    Abstract:

    Background and Aims Previous studies demonstrated that miR-574-5p is closely associated with the prognosis of a variety of tumors. However, the relationship between miR-574-5p and hepatocellular carcinoma (HCC) has not been reported yet. Therefore, this study was designed to investigate the expression of miR-574-5p in HCC and its relationship with prognosis of the patients.Methods The expressions of miR-574-5p in 130 paired specimens of HCC and adjacent tissue as well as in HCC cell lines (HepG2 and MHCC-97H) and normal hepatic cell line (L-02) were detected by qRT-PCR method. After the optimal cut-off value of miR-574-5p expression level was determined from the survival data of the patients using X-tile software, the relations of miR-574-5p expression with the clinicopathologic factors and postoperative survival rates of the patients were analyzed. The influencing factors for the prognosis of HCC patients were determined. The target genes of miR-574-5p were predicted by TargetScan, and then were verified by dual-luciferase reporter assay and confirmed by Western blot analysis.Results The expression levels of miR-574-5p were significantly increased in HCC tissue than that in adjacent tissue, and increased in HCC cell lines than that in normal hepatic cell line (all P<0.05). The expression of miR-574-5p was significantly associated with TNM stage (P=0.002) and degree of differentiation (P=0.000). Both overall survival rate and tumor-free survival rate were significantly lower in patients with high miR-574-5p expression than those in patients with low miR-574-5p expression (both P<0.01). The results of univariate and multivariate analysis showed that high miR-574-5p expression (HR=4.101, 95% CI=1.348-8.968, P=0.03), stage III-IV (HR=5.403, 95% CI=1.266-13.860, P=0.02) and moderate/poor differentiation (HR=3.655, 95% CI=2.165-6.984, P=0.00) were independent risk factors for overall survival of HCC patients, and high miR-574-5p expression (HR=7.168, 95% CI=1.144-18.260, P=0.01) and stage III-IV (HR=7.436, 95% CI=1.123-20.916, P=0.00) were independent risk factors for disease-free survival of HCC patients. Targetscan software analysis showed that there was a direct binding site between FOG2 and miR-574-5p, and dual luciferase reporter gene assay showed that FOG2 was the target gene of miR-574-5p. Western blot analysis showed that the protein expression level of FOG2 in HCC tissue was lower than that in adjacent tissue, and Pearson correlation analysis showed that the miR-574-5p expression was negatively correlated with the protein expression of FOG2 in HCC tissue (r=-0.499, P<0.05).Conclusion The expression of miR-574-5p is generally increased in HCC. High miR-574-5p expression can be considered as a molecular marker for poor prognosis of HCC patients. MiR-574-5p may probably exert a tumor-promoting action through down-regulating its target gene FOG2.

    表 1 miR-574-5p的表达和临床病理因数的关系[n(%)]Table 1 The relationship between the expression of miR-574-5p and clinicopathologic parameters [n (%)]
    表 3 影响HCC预后的多因素分析Table 3 Multivariate analysis of factors for the prognosis of HCC
    图1 组织及细胞系中miR-574-5p 表达水平的比较 A: miR-574-5p在HCC癌及癌旁组织中的表达比较;B:miR-574-5p在HCC细胞系及正常肝细胞系中的表达比较Fig.1 Comparison of the expression level of miR-574-5p in HCC tissues and cell lines A: Comparison of the expression of miR-574-5p in HCC and adjacent tissues; B: The expression of miR-574-5p in HCC cell lines and normal liver cell line
    图2 miR-574-5p的表达与HCC患者预后的关系 A:总生存曲线;B:无瘤生存曲线Fig.2 The relationship between the expression of miR-574-5p and the prognosis of HCC patients A: Overall survival curve; B: Tumor-free survival curve
    图3 miR-574-5p的靶基因分析 A:FOG2与miR-574-5p存在结合靶点;B:双萤光素酶实验验证FOG2是miR-574-5p的靶标Fig.3 Analysis of the target genes of miR-574-5p A: Binding site between FOG2 and miR-574-5p; B: Dual luciferase assay verifying that FOG2 is the target of miR-574-5p
    图4 FOG2的表达及其与miR-574-5p表达的关系 A:Western blot检测FOG2在HCC及癌旁组织中的表达;B:FOG2表达与miR-574-5p的相关性分析Fig.4 FOG2 expression and its relation with miR-574-5p expression A: Western blot experiment shows the expression of FOG2 in cancer and adjacent tissues; B: Correlation analysis of FOG2 expression and miR-574-5p
    表 2 影响HCC预后的单因素分析Table 2 Univariate analysis of factors for the prognosis of HCC
    参考文献
    相似文献
    引证文献
引用本文

李乾,郭清皓.肝细胞癌中miR-574-5p的表达与作用及其与预后的关系[J].中国普通外科杂志,2021,30(8):926-933.
DOI:10.7659/j. issn.1005-6947.2021.08.007

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:2020-12-27
  • 最后修改日期:2021-07-20
  • 录用日期:
  • 在线发布日期: 2021-09-02